Tranexamic Acid in the Control of Uterine Atony During Labor by Haj Seyed Javadi, Ezzatossadat et al.
Biotech Health Sci. 2015 May; 2(2): e26898. 
Published online 2015 May 23. Research Article
Tranexamic Acid in the Control of Uterine Atony During Labor
Ezzatossadat Haj Seyed Javadi 
1
; Zoya Sadeghipour 
1
; Ameneh Barikani 
1,*
; Maryam Javadi 
1
1Children Growth Research Center, Qazvin University of Medical Sciences, Qazvin, IR Iran*Corresponding author: Ameneh Barikani, Children Growth Research Center, Qazvin University of Medical Sciences, Qazvin, IR Iran. Tel: +98-2833328709, Fax: +98-2833344088, 
E-mail: barikani.a@gmail.com
 Received: March 16, 2015; Accepted: April 14, 2015
Background: Death from hemorrhage is still the leading cause of maternal mortality.
Objectives: The aim of this study was to determine the effect of tranexamic acid on the control of uterine atony during labor.
Patients and Methods: A randomized clinical trial was conducted on 90 pregnant women who had uterine atony in Qazvin, during the 
year 2012. The control group (n = 45) received the routine treatment of uterine atony. The second group (n = 45), in addition to the routine 
treatments, received 1 gram of tranexamic acid diluted in 100 mL saline of 5% dextrose in water by intravenous infusion within 10 minutes. 
The amount of blood loss, changes in hemoglobin level, need for surgical intervention and transfusion of blood products and duration of 
hospitalization were compared between the two groups. Data were analyzed using the chi-square test and t test.
Results: Hemoglobin level was 9.9 ± 5.1 in the control group six hours after hemorrhage while it was 8.10 ± 2.1 in the treatment group 
(P = 0.004). Hemoglobin level was 5.8 ± 4.1 in the control who did not receive transfusion of blood products during the first 24 hours 
after hemorrhage, while this level was 7.9 ± 4.1 in the treatment group (P = 0.001). The amount of bleeding significantly declined in the 
intervention group compared to the control group (P < 0.001). Moreover, the need for transfusion of blood products decreased by a third 
(P < 0.001) while the number of hospitalization days significantly decreased as well (P < 0.04).
Conclusions: Tranexamic acid can significantly reduce the rate of postpartum hemorrhage.
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1. Background
Every year nearly 530 thousand women die of preg-
nancy and pregnancy-related complications around the 
world. One of the main causes of maternal mortality in 
the world is obstetric hemorrhage. The World Health Or-
ganization (WHO) estimated that 25% of maternal deaths 
in the world were due to severe bleeding after childbirth 
in 1990, and morbidity rate caused by severe bleeding 
after childbirth was estimated at 20 million each year (1, 
2). Given that, mothers were admitted to the hospital for 
delivery, where there are abundant blood products for 
transfusion, maternal mortality rates markedly declined.
However, death from hemorrhage is still the leading 
cause of maternal mortality (3). More than 18% of mater-
nal deaths were related to pregnancy and were directly 
caused by postpartum hemorrhage based on the results 
of the Centers for Disease Control and Prevention of the 
United States from 1977 to the end 1991. Half of all postpar-
tum deaths are due to severe postpartum hemorrhage in 
developing countries (3, 4). The uterine atony can be con-
sidered as the most important cause of obstetric hemor-
rhage. Correct and active management of uterine con-
traction medications and other important measures are 
essential in treatment of this disease. In order to inhibit 
the activation of the fibrinolytic system, anti-fibrinolytic 
drugs such as tranexamic acid should be used.
Several studies were conducted on tranexamic acid 
for reduction of hemorrhage during surgery and con-
sequently reduction in the need for blood transfusions 
in patients under anesthesia during spinal surgery, 
urinary tract surgery, orthopedics, cardiac surgery and 
liver transplantation. The prophylactic administration 
of anti-fibrinolytic drugs such as tranexamic acid was 
also proposed despite differences of opinions between 
researches. It was noted that this medication improves 
blood homeostasis in certain recovery procedures (5). An-
ti-fibrinolytic amino acid drugs such as tranexamic acid 
or 4-amino-methyl cyclohexane carboxylic acid act by re-
versible binding to plasminogen and inhibit the binding 
of plasminogen to fibrin and activation of conversion to 
plasmin. This ultimately results in delay in fibrinolysis 
and degradation of the formation of blood clots. In other 
words, these drugs improve the clot structure and stabil-
ity by inhibiting tissue fibrinolysis (6, 7).
Immediately after removal of the placenta, fibrinogen 
and fibrin are degraded rapidly, whereas the plasmino-
gen activator and fibrin degradation products are in-
creased by the activation of the fibrinolytic system. This 
activation can cause severe postpartum hemorrhage 
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about six to ten hours after delivery (6). Tranexamic acid 
inhibits the binding of fibrin to plasminogen in the ho-
meostasis procedure, which is essential for binding to 
fibrin. The mechanism of action of this drug may inacti-
vate the plasminogen binding on fibrin surfaces. It also 
inhibits fibrin degradation (8). The half-life of this drug 
is approximately 80 minutes provided that renal func-
tion is normal. Its side effects are dose dependent. Often, 
gastrointestinal symptoms such as nausea and vomiting, 
abdominal pain, and diarrhea are reported as side effects 
of this drug (6). The main risk of this drug is thrombo-
embolic complications, which are caused by the inhibi-
tion of fibrinolysis. This inhibition is the natural defense 
mechanism against thrombosis formation (6). However, 
the risk of thrombosis formation was not reported in in-
travenous injection of tranexamic acid drug during sur-
gery (9). In order to prevent postpartum hemorrhage to 
reduce maternal mortality, it is logical to conduct a study 
on prescription of tranexamic acid to control postpar-
tum hemorrhage (2). Several studies were conducted on 
this drug and its role in the control of postpartum hem-
orrhage, which consequently leads to less need for blood 
transfusions. However, an adequate number of studies 
was not conducted on the role of this drug to control 
postpartum hemorrhage (2).
2. Objectives
The purpose of this study was to investigate the effect 
of tranexamic acid drug in the treatment of uterineatony 
during labor (whether caesarean section or vaginal sur-
gery). This study was conducted in order to reduce post-
partum hemorrhage and control cardiovascular hemo-
dynamics with the purpose of minimal side effects in the 
patients. It was also designed in order to prevent morbid-
ity of pregnant woman.
3. Patients and Methods
This study was a randomized clinical trial. It was con-
ducted on 90 pregnant women who visited the Kosar 
hospital of Qazvin. All patients met the inclusion criteria 
of the study. None of the patients were excluded from the 
study. Patients who were included in the study were diag-
nosed by a gynecologist with uterine atony during cesar-
ean section or vaginal delivery.
The patients were randomly allocated to two equal 
groups, including the treatment and the control group. 
Each group consisted of 45 patients. Both groups re-
ceived 30 units of oxytocin in 1000 mL of normal saline 
as infusion upon delivery. In addition the control group 
received 20 units of oxytocin and 0.2 mg of methergine 
as well as uterine massage. The intervention group, in ad-
dition to the above routine measures, received one gram 
of tranexamic acid diluted in 100 mL saline of 5% dextrose 
in water by intravenous infusion within 10 minutes. The 
anesthesia method in patients undergoing cesarean sec-
tion was spinal or epidural. When the patients were ad-
mitted to the maternity ward, a blood sample was taken 
from each of them for Complete Blood Count (CBC), Rh 
(Rhesus factor), BG (Blood Group) or blood cross-match-
ing. After delivery and conducting the above measures, 
the patients were monitored for vital signs (blood pres-
sure, heart rate, RR (Respiratory rate), and temperature), 
urinary output, and the amount of uterine hemorrhage 
and contraction every 15 minutes for up to two hours. The 
CBC test was retaken from the patients under study (both 
intervention and control groups) at 6 and 24 hours after 
the hemorrhage. The indication was the prescription of 
cell pack; the hemoglobin level was less than or equal to 
seven or the vital signs were unstable.
3.1. Method of Data Collection and the Tools for Col-lecting the Data
The information about the patients under study was 
collected by a check-list. This information included age, 
parity, mode of delivery, history of disease, Body Mass In-
dex (BMI), weight of the infant, hemoglobin level on ad-
mission, hemoglobin level at 6 and 24 hours after drug 
administration, the need for transfusion of blood prod-
ucts, the need for surgical interventions and duration of 
hospitalization after delivery.
3.2. Methods 
This study was conducted on 90 pregnant women who 
were diagnosis by a gynecologist with atony during la-
bor. This study was conducted at the Kosar hospital of Qa-
zvin during 2012. The delivery procedures included both 
cesarean section and vaginal delivery. All 90 patients met 
the inclusion criteria of the study. None of the patients 
was excluded from the study. All the pregnant women 
were diagnosed by a gynecologist with atony after de-
livery by either cesarean section or vaginal delivery and 
they were all included in the study. Atony is presented by 
significant uterine prolapse with hemorrhage of more 
than 500 mL after vaginal delivery or more than 1000 
mL after cesarean section or hemorrhage that causes un-
stable vital signs in the patient. The exclusion criteria of 
the research included patients with a history of cardio-
vascular disease, liver disease, kidney disease, hemolytic 
disease blood-clotting disorders and those with a history 
of thromboembolism or thrombophlebitis and those 
who received general anesthesia for cesarean section. 
The amount of bleeding in the patients with vaginal de-
livery was calculated by visual estimation and weight of 
the blood in the dish under the patient. This level in pa-
tients with cesarean section was calculated by estimated 
measurement of the gas and gas Leung, and the amount 
of blood in the suction. The amount of bleeding was clas-
sified to three levels 500 mL to 1000 mL, 1000 mL to 2000 
mL and more than 2000 mL. In order to evaluate changes 
in hemoglobin level, the patients who had not received 
transfusion of blood products were evaluated during the 
first 24 hours of delivery. The indication was prescrip-
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tion of cell pack for the patients; the hemoglobin level 
was less than or equal to seven or the vital signs of the 
patients were unstable.
3.3. The Method to Describe the Data and Data Analysis
The Data were collected through a check list. Then, the 
collected data was entered in the SPSS 16 software. The 
data was evaluated using t test and chi-square tests. The 
P value was determined as P < 0.05. 
First, the terms of the research was described to the 
patients under study. Although side effects of tranexam-
ic drug are minimal and spontaneously limiting, the 
pregnant women under study were given an informed 
consent form. The informative form with information 
relevant to the investigation and the complete address 
and telephone number of the person responsible for the 
study were given to the patients and their husbands, so 
that they could obtain complete information about the 
trial. Written informed consent was obtained from the 
subjects, so that they could participate in the study.
4. Results
Among the 90 pregnant women participating in this 
study, 45 patients were placed in the control group while 
45 patients were in the intervention group. The patients 
in the intervention group received the tranexamic drug. 
The BMI of the patients was the same in both groups. The 
mean age of the subjects in the control group was 24.7 ± 
56.5 years old while this figure was 19.24 ± 23.5 years old 
in the intervention group. There was no significant differ-
ence regarding the age of the subjects between the two 
groups (P = 0.9). Regarding parity, 6.84% (38 cases) of the 
participants in the control group had a parity less than 
or approximately equal to three while 6.15% (7 patients) 
had a parity greater than three. In the intervention group, 
6.95% (n = 43) had a parity less than or equal to three and 
4.4% (2 patients) had a parity more than three. This differ-
ence was not significant (P = 0.15). Regarding the type of 
delivery, 40% (n = 18) had vaginal delivery while 60% (27 pa-
tients) had cesarean delivery in the control group. In the 
intervention group, 9.48% (22 patients) had vaginal deliv-
ery while 1.51% (23 patients) had cesarean delivery. This dif-
ference was also not significant (P = 0.52). Approximately, 
seven patients in the control group and five patients 
in the intervention group needed transfusion of blood 
products during the first 24 hours after delivery. These 
patients were not considered in the procedure of measur-
ing change in hemoglobin level in the two groups (note 
that this difference was not statistically significant). Next, 
changes in hemoglobin level were measured among pa-
tients who received transfusion of blood products during 
the first 24 hours after delivery (38 patients in the control 
group and 41 patients in the intervention group). Overall, 
8.57% (26 patients) of patients needed to receive a cell pack 
in the control group while this figure was 20% (nine pa-
tients) in the intervention group. This difference was sta-
tistically significant (P = 0.001). In the control group, four 
patients (8.8%) and in the intervention group two patients 
(4.4%) were found to need FFP (Fresh-Frozen Plasma). This 
difference was not significant (P = 0.67). About three cases 
(6.6%) from control subjects needed to receive platelet 
while no patients were needed to receive platelet in the 
intervention group. This difference was also not statisti-
cally significant (0.4). Approximately 14 cases (1.31%) of the 
control group and eight patients (8.17%) in the interven-
tion group underwent uterine artery ligation. The differ-
ence was not significant (P = 0.22). About three patients in 
the control group (7.6%) and one patient (2.2%) in the in-
tervention group underwent hypogastric artery ligation. 
This difference was not significant (P = 0.61). The need for 
hysterectomy in the control group was observed in two 
patients (2.2%) and no need for hysterectomy was seen in 
the intervention group. The difference was not significant 
(P = 0.49) (Table 1).
Regarding the hemoglobin level on admission of the 
patients, there was no significant difference between the 
two groups (P = 0.26). The hemoglobin level on the time 
of admission of the patients in the control group was 
7.11 ± 5.1 while this level was 1.12 ± 1.1 in the intervention 
group. The hemoglobin level at six hours after the hem-
orrhage was 7.9 ± 5.1 in the control group while this level 
was 6.10 ± 3.1 in the intervention group. This difference 
was statistically significant (P = 0.004). The hemoglobin 
level was 5.8 ± 4.1 at 24 hours after bleeding in the con-
trol group while this level was 7.9 ± 4.1 in the intervention 
group. This difference was statistically significant (P = 
0.001) (Table 2).
The amount of bleeding in the control group was less 
than 1000 mL in two patients (20%), while in the interven-
tion group the amount of bleeding less than 1000 mL was 
in 16 patients (6.35%). This difference was significant (P = 
0. 001) (Table 3).
The number of hospitalization days in the control 
group was 8.3 ± 7.1 days while this figure was 9.2 ± 82.0 in 
the intervention group. This was statistically significant 
(P = 0.004). In this study, no adverse effects of throm-
boembolism caused by prescription of tranexamic acid 
drug were seen in the patients after delivery.
Table 1.  Comparison of the Frequency of Patients Who Needed 
Transfusion of Blood Products and Surgical Intervention in 
Both Groups a,b
Variables Control c Case c P Value
Yes No Yes No
Packed cell 28.9 21.1 10 40 0.001
FFP 4.4 45.6 2.2 47.8 0.67
Platelets 3.3 46.7 0 50 0.24
Uterine artery ligation 15.6 34.4 8.9 41.1 0.22
Hysterectomy 2.2 47.8 0 50 0.49
Hypogastric artery ligation 3.3 46.7 1.1 48.9 0.61
a  Abbreviation: FFP, Fresh-Frozen Plasma.
b  Data are presented for 90 patients.
c  Data are presented for 45 patients.
Haj Seyed Javadi E et al.
Biotech Health Sci. 2015;2(2):e268984
Table 2.  The Frequency Distribution, Mean and Standard Devia-
tion of the Hemoglobin Level in the Intervention and Control 
Groups on Admission, 6 and 24 Hours After Bleeding a
Hgb Control b Case c P Value
First 11.17 ± 1.5 12.1 ± 1.1 0.2
6 hours 9.7 ± 1.4 10.8 ± 1.2 0.004
24 hours 8.4 ± 1.4 9.9 ± 1.5 0.004
a  Abbreviation: Hgb, Hemoglobin.
b  Data are presented for 48 patients.
c  Data are presented for 41 patients.
Table 3.  The Frequency Distribution of the Amount of Bleeding 
in the Intervention and Control Groups a
Total Case Control P Value
Amount of Bleeding 0.001
500 - 1000, mL 6.7 17.8 2.3
1000 - 2000, mL 73.3 31.1 42.2
> 2000, mL 20 1.1 5.6
a  Data are presented for n = 90.
5. Discussion
This study investigated the effect of tranexamic acid 
drug on uterine atony during labor. Based on the results 
of this study, there was no significant difference regard-
ing age, mode of delivery, hemoglobin level on admis-
sion of the patient and parity between the two groups. 
The results indicated that the amount of bleeding and 
the need to receive a cell pack and changes in hemoglo-
bin levels in patients who received tranexamic acid signif-
icantly declined compared to the control group who did 
not receive this medication. Moreover, the mean number 
of hospitalization days also decreased in the intervention 
group compared to the control group. There were no sig-
nificant differences between the two groups regarding 
the need for invasive procedures (uterine artery ligation 
and hypogastric artery ligation). Moreover, there was no 
significant difference between the two groups regarding 
the need for emergency hysterectomy. In our study, no 
complications relevant to thromboembolism and other 
side effects related to tranexamic acid were observed. 
No case of mortality was observed during the follow-up. 
In addition, all infants were born healthy without any 
problems. There was no significant difference regard-
ing the need for receiving FFP and platelets between the 
two groups under study. In the study of Horrow et al. (3) 
tranexamic medication clearly reduced obstetric hemor-
rhage from the time of delivery up to two hours (7.42 ± 40 
in the treatment group and 77 ± 9.73 in the control group) 
(P = 0.001). No drug-related side effects were observed in 
this study. It was concluded that tranexamic acid could 
safely reduce hemorrhage after cesarean section. The 
results of the above-mentioned study were in line with 
those obtained by our study. However, the subjects un-
der study in the above study were all primipara women 
and only women who underwent cesarean section were 
evaluated. On the other hand, in our study, all subjects 
including both primipara and multipara women were 
studied. Our study also included both types of delivery 
(vaginal delivery and cesarean section). In another study 
conducted by Ferrer et al. (10) it was concluded that 
tranexamic medication could reduce postpartum hem-
orrhage by 92 mL in the intervention group. In this study, 
the most common side effect of this drug was vomiting, 
as reported by the patients. In our study, no drug-related 
side effect was reported. However, in terms of reducing 
the amount of bleeding, the volumes of blood loss re-
ported in our study were in line with those reported in 
the above study. Although the sample size was large in 
the above study, only cases with vaginal delivery were 
examined. Novikova et al. conducted a study on 273 pa-
tients in 2010 (2). In their study, it was concluded that 
prescription of 1 g tranexamic medication for controlling 
postpartum hemorrhage in the first group had no signifi-
cant difference with prescription of 500 mg tranexamic 
medication in the second group. However, prescription 
of 1 g tranexamic medication in the second group signifi-
cantly reduced postpartum hemorrhage compared to 
the third group who did not receive this medication. In 
our study, all patients in the intervention group received 
1 g of intravenous tranexamic infusion spontaneously af-
ter delivery. The second dose of the drug might have been 
repeated at the same dose 30 minutes later if needed.
Shakur et al. conducted a study on 15000 patients 
with atony after cesarean section in 2010 and exam-
ined the impact of venous tranexamic infusion in con-
trolling hemorrhage (11). In their study, it was revealed 
that tranexamic medication decreases the hemorrhage 
caused by uterine atony. They also found that this medi-
cation could reduce postpartum hysterectomy by three 
to four percent. This study was more precisely conduct-
ed considering its large sample size and the placebo ef-
fect of the drug compared to our study. However, the 
results of our study were in line with those obtained 
by the above study in terms of reducing blood loss af-
ter delivery. In the study of Eftekharian et al. on 40 
pregnant women in 2008 (5), it was revealed that the 
control group needed transfusion of blood products 
almost double the number of blood transfusions in 
the treatment group. Moreover, the amount of blood 
loss was clearly reduced in the treatment group com-
pared to the control group. As a result, it was revealed 
that tranexamic medication reduces hemorrhage dur-
ing surgery. In this study, the sample size was less than 
our study. On the other hand, in our study, the dose of 
tranexamic medication was 1 g for all patients. The re-
sults of this study were in line with those obtained by 
our study regarding the reduced need for transfusion 
of blood products. None of the reviewed studies, ex-
amined and compared the hospitalization days of the 
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patients. However, we examined this in our study and 
found a significant difference between the control and 
intervention groups. Nevertheless, it is essential to con-
duct several other studies examining this issue in order 
to confirm the results obtained in this study regarding 
hospitalization days. In none of the studies, the need for 
platelet and FFP was examined between the two groups, 
whereas we evaluated this issue in this study. However, 
no difference was observed between the two groups. 
Cumulative incidences of emergency hysterectomy are 
different in different parts of the world. However, it is 
estimated to be between 1.25% and 0.04% for all births. In 
a prospective study conducted by Nayama (12) in 2006, 
the incidence of hysterectomy due to uterine atony was 
reported as 8.26%. In the study conducted by Eftekharian 
Jahromi et al. (5) it was reported that the incidence of 
hysterectomy decreased by a third in the intervention 
group. In the study conducted by Shakur et al. (11) it was 
reported that the incidence of hysterectomy was de-
creased by 3 - 4% in the intervention group. In our study, 
two patients (4.4%) of the control group needed hyster-
ectomy while no patient needed hysterectomy in the 
intervention group. Although no significant differences 
were observed between the two groups, tranexamic acid 
medication can be effective in reducing postpartum 
emergency hysterectomy.
In conclusion, based on previous studies and our study, 
the prescription of tranexamic acid can be effective for 
controlling uterine atony and reducing the hemorrhage 
caused by this atony. This medication can also be used to 
reduce the need for transfusion of blood products. It may 
also be used to control bleeding caused by atony.
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